Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 45, Issue 8, 2006, Pages 919-927

  Kratochvil, Christopher J ^a,e   Wilens, Timothy E ^b   Greenhill, Laurence L ^c   Gao, Haitao ^d   Baker, Kurt D ^d   Feldman, Peter D ^d   Gelowitz, Douglas L ^d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder; Pediatric patients

Indexed keywords

ATOMOXETINE;

ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CHILD; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; GASTROINTESTINAL SYMPTOM; GROWTH; HEADACHE; HUMAN; INFLUENZA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; PRIORITY JOURNAL; RHINOPHARYNGITIS; SORE THROAT; STATISTICAL SIGNIFICANCE; UPPER RESPIRATORY TRACT INFECTION;

EID: 33746448711     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.chi.0000222788.34229.68     Document Type: Article

References (42)

1. Allen AJ, Wernicke JF, Dunn D et al. (2002), Safety and efficacy of atomoxetine in pediatric CYP2D6 extensive vs. poor metabolizers. Biol Psychiatry 51:37S
2. American Psychiatric Association (2000), Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association
3. Biederman J, Faraone S, Monuteaux MC, Grossbard JR (2004), How informative are parent reports of attention-deficit/hyperactivity disorder symptoms for assessing outcome in clinical trials of long-acting treatments? A pooled analysis of parents' and teachers' reports. Pediatrics 113:1667-1671
4. Biederman J, Newcorn J, Sprich S (1991), Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 148:564-577
5. Buitelaar JK (2001), Epidemiological aspects: what have we learned over the last decade. In: Hyperactivity Disorders, Sandberg S, ed. Cambridge, U.K.: Cambridge University Press, pp 30-63
6. Bymaster FP, Katner J, Nelson DL et al. (2002), Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711
7. Conners CK (1997), Conners Rating Scales: Revised Technical Manual. North Tonawanda, NY: Multi-Health Systems
8. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998), ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York: The Guilford Press
9. Faries DE, Yalcin I, Harder D, Heiligenstein JH (2001), Validation of the ADHD rating scale as a clinician administered and scored instrument. J Atten Disord 5:39-47
10. Greenhill LL (1998), The use of psychotropic medication in preschoolers: indications, safety, and efficacy. Can J Psychiatry 43:576-581
11. Guy W (1976), ECDEU Assessment Manual For Psychopharmacology, Revised. Publication ADM 76-338. Bethesda, MD: U.S. Department of Health, Education, and Welfare
12. Kaufman J, Birmaher B, Brent D, Rao U, Ryan N (1996), Kiddie-SADS-Present and Lifetime Version (K-SADS-PL). Pittsburgh: University of Pittsburgh Press
13. Kelsey DK, Sumner CR, Casat CD et al. (2004), Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 114:e1-e8
14. Kratochvil CJ, Heiligenstein JH, Dittmann R et al. (2002a), Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 41:776-784
15. Kratochvil CJ, Wernicke J, Schuh K, Zhang S, Faries D, Kelsey D (2002b), Long-term safety of atomoxetine in children treated for ADHD. Paper presented at: 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, October 22-27
16. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flega M, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL (2000), CDC Growth Charts: United States. Advance Data From Vital and Health Statistics. Report Nr. 314. Hyattsville, MD: National Center for Health Statistics
17. Lavigne JV, Gibbons RD, Christoffel KK et al. (1996), Prevalence rates and correlates of psychiatric disorders among preschool children. J Am Acad Child Psychiatry 35:204-214
18. Lisska MC, Rivkees SA (2003), Daily methylphenidate use slows the growth of children: a community based study. J Pediatr Endocrinol Metab 16:711-718
19. Masi G, Cosenza A, Mucci M, Brovedani P (2003), A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 64:1039-1047
20. Michelson D, Adler L, Spencer T et al. (2003), Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112-120
21. Michelson D, Allen AJ, Busner J et al. (2002), Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901
22. Michelson D, Buitelaar J, Danckaerts MJ et al. (2004), Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 43:896-904
23. Michelson D, Faries D, Wernicke J et al. (2001), Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:e83
24. MTA Cooperative Group (1999), A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1073-1086
25. National Heart Lung and Blood Institute (1987), Report of the second task force on blood pressure control in children-1987. Task force on blood pressure control in children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. Pediatrics 79:1-25
26. Popper CW (2000), Pharmacological alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 9:605-646
27. Poulton A, Cowell CT (2003), Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health 39:180-185
28. Rapport MD, Moffitt C (2002), Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev 22:1107-1131
29. Spencer T, Biederman J Heiligenstein J et al. (2001), An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactiviry disorder. J Child Adolesc Psychopharrmcol 11:251-265
30. Spencer T, Heiligenstein JH, Biederman J et al. (2002), Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63: 1140-1147
31. Spencer TJ (2003), Treatment for ADHD with OROS methylphenidate: long-term effect on growth. Proceedings Summary of the 156th Annual Meeting of the American Psychiatric Association, San Francisco, May 17-22, p 268
32. Sund AM, Zeiner P (2002), Does extended medication with amphetamine or methylphenidate reduce growth in hyperactive children? Nord J Psychiatry 56:53-57
33. Sutton V, Milton D, Ruff D, Allen AJ (2004a), Atomoxetine efficacy over time in children and adolescents with ADHD. In: Scientific Proceedings of the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, October 19-24, p 157
34. Sutton V, Milton D, Ruff D, Allen AJ (2004b), Long term effects of atomoxetine on growth in children with ADHD. In: Scientific Proceedings of the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, October 19-24, p 132
35. Weiss M, Tannock R, Kratochvil C et al. (2005), A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 44:647-655
36. Wernicke JF, Kratochvil C, Milton D et al. (2002), Long-term safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder. In: Proceedings Summary of the 155th Annual Meeting of the American Psychiatric Association, Philadelphia, May 18-23, p 92
37. Wigal SB, Steinhoff K, McGough JJ et al. (2004), Analog classroom study of amphetamine XR and atomoxetine for ADHD. In: Scientific Proceedings of the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, October 19-24, p 135
38. Wilens T, Pelham W, Stein M et al. (2003a), ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 42:424-433
39. Wilens TE, Biederman J, Brown S et al. (2003b), Psychiatric comorbidity and functioning in clinically referred preschool children and school-age youths with ADHD. J Am Acad Child Adolesc Psychiatry. 41:262-268
40. Wilens TE, Kratochvil C, Newcorn JH, Gao H (2006), Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry 45:149-157
41. World Medical Association (2000), Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects. As adopted by the 18th General Assembly, Helsinki, Finland, June 1964 and amended by the 52nd General Assembly, Edinburgh, October
42. Zuddas A, Di Martino A, Muglia P, Cianchetti C (2000), Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 10:79-90